IntelGenx Corp. Achieves Positive Pivotal Study Results for Bioequivalent Anti-Migraine VersaFilm Formulation of Maxalt-MLT(R)

Published: May 29, 2012

SAINT LAURENT, Quebec, May 29, 2012 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) ("IntelGenx") today announced the completion of the pivotal bioequivalence study for a novel oral thin-film formulation of Rizatriptan, the active drug in Maxalt-MLT® orally disintegrating tablets. Maxalt-MLT® is a leading branded anti-migraine product manufactured by Merck & Co. According to Merck's most recent annual report, sales of Maxalt® grew 16% to $639 million in 2011. The thin-film formulation of Rizatriptan has been developed using IntelGenx' proprietary immediate release "VersaFilm" drug delivery technology.

Back to news